N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of less than 10%, owing to its late-stage diagnosis. Early detection of pancreatic cancer (PC) can significantly increase survival rates. To identify the serum biomarker signatures associated with early-stage P...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastrointestinal oncology Vol. 16; no. 3; pp. 659 - 669
Main Authors Wen, Yan-Rong, Lin, Xia-Wen, Zhou, Yu-Wen, Xu, Lei, Zhang, Jun-Li, Chen, Cui-Ying, He, Jian
Format Journal Article
LanguageEnglish
Published China Baishideng Publishing Group Inc 15.03.2024
Subjects
Case Control Study
Biomarkers
Predictive modeling
N-glycans
Glycomics
Pancreatic cancer
Online AccessGet full text

Cover

More Information
Summary:Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of less than 10%, owing to its late-stage diagnosis. Early detection of pancreatic cancer (PC) can significantly increase survival rates. To identify the serum biomarker signatures associated with early-stage PDAC by serum N-glycan analysis. An extensive patient cohort was used to determine a biomarker signature, including patients with PDAC that was well-defined at an early stage (stages I and II). The biomarker signature was derived from a case-control study using a case-cohort design consisting of 29 patients with stage I, 22 with stage II, 4 with stage III, 16 with stage IV PDAC, and 88 controls. We used multiparametric analysis to identify early-stage PDAC N-glycan signatures and developed an N-glycan signature-based diagnosis model called the "Glyco-model". The biomarker signature was created to discriminate samples derived from patients with PC from those of controls, with a receiver operating characteristic area under the curve of 0.86. In addition, the biomarker signature combined with cancer antigen 19-9 could discriminate patients with PDAC from controls, with a receiver operating characteristic area under the curve of 0.919. Glyco-model demonstrated favorable diagnostic performance in all stages of PC. The diagnostic sensitivity for stage I PDAC was 89.66%. In a prospective validation study, this serum biomarker signature may offer a viable method for detecting early-stage PDAC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Co-corresponding authors: Cui-Ying Chen and Jian He.
Co-first authors: Yan-Rong Wen and Xia-Wen Lin.
Author contributions: All authors contributed to the study conception and design. Wen YR and Lin XW contributed equally to this work; Lin XW and He J collected the samples and conducted the data analysis; Zhou YW, Xu L, Zhang JL, and Chen CY performed N-glycans analysis; Wen YR and He J designed the research, analyzed data and wrote the manuscript. He J and Chen CY are the co-corresponding authors of this study. He J and Chen CY were involved in the experimental design and revision of the article. Specifically, He J assumed responsibility for the overall design of the subject, Chen CY focused on the experimental design of the N-glycan analysis.
Supported by fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University, No. 2021-LCYJ-MS-11.
Corresponding author: Jian He, Doctor, PhD, Chief Doctor, Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China. hjxueren@126.com
ISSN:1948-5204
1948-5204
DOI:10.4251/wjgo.v16.i3.659